Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Bullishness Or Belligerence At Roche And Biogen?

Biogen And Roche’s First-Quarter Results Make Unusual Bedfellows

Executive Summary

After only two weeks of the first-quarter 2020 earnings season for biopharmaceutical companies, the tempo of the announcements seems already to have been defined. Unless companies are exposed to, on the one hand, medical devices, or on the other, consumer health or diagnostics, the impact of the coronavirus pandemic on pure play biopharmaceutical companies has so far been marginal.

You may also be interested in...



Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy.

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy

Stockwatch: Investors Reward Rose-Tinted Guidance

After three weeks of the first-quarter 2020 earnings season, the coronavirus pandemic has left pure-play pharmaceutical companies in a much better position than many other sectors. One of the reasons behind this has been channel stocking. As some companies have learnt in the past, this can be a double-edged sword.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel